<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37004478</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3252</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)</Title><ISOAbbreviation>J Trace Elem Med Biol</ISOAbbreviation></Journal><ArticleTitle>Metal ratios as possible biomarkers for amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>127163</StartPage><MedlinePgn>127163</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jtemb.2023.127163</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0946-672X(23)00039-1</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with unknown aetiology. Metals have been suspected to contribute to ALS pathogenesis since mid-19th century, yet studies on measured metal concentrations in ALS patients have often yielded conflicting results, with large individual variation in measured values. Calculating metal concentration ratios can unveil possible synergistic effects of neurotoxic metals in ALS pathogenesis. The aim of this study was to investigate if ratios of different metal concentrations in cerebrospinal fluid (CSF) and blood plasma, respectively, differ between ALS patients and healthy controls.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Cerebrospinal fluid and blood plasma were collected from 17 ALS patients and 10 controls. Samples were analysed for 22 metals by high-resolution inductively coupled plasma mass spectrometry (HR-ICP-MS), and all possible 231 metal ratios calculated in each body fluid.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fifty-three metal ratios were significantly elevated in ALS cases as compared to controls (p&#xa0;&lt;&#xa0;0.05); five in blood plasma, and 48 in CSF. The finding of fewer elevated ratios in blood plasma may indicate specific transport of metals into the central nervous system. The elevated metal ratios in CSF include Cd/Se (p&#xa0;=&#xa0;0.031), and 16 ratios with magnesium, such as Mn/Mg (p&#xa0;=&#xa0;0.005) and Al/Mg (p&#xa0;=&#xa0;0.014).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Metal ratios may be used as biomarkers in ALS diagnosis and as guidelines for preventive measures.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier GmbH.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koski</LastName><ForeName>Lassi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden. Electronic address: lassi.koski@stud.ki.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berntsson</LastName><ForeName>Elina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Chemistry Section, Arrhenius Laboratories, Stockholm University, 106 91 Stockholm, Sweden; Department of Chemistry and Biotechnology, Tallinn University of Technology, 19086 Tallinn, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vikstr&#xf6;m</LastName><ForeName>Max</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>W&#xe4;rml&#xe4;nder</LastName><ForeName>Sebastian K T S</ForeName><Initials>SKTS</Initials><AffiliationInfo><Affiliation>Chemistry Section, Arrhenius Laboratories, Stockholm University, 106 91 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roos</LastName><ForeName>Per M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Institute of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden; Department of Clinical Physiology, St. G&#xf6;ran Hospital University Unit, 112 81 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Trace Elem Med Biol</MedlineTA><NlmUniqueID>9508274</NlmUniqueID><ISSNLinking>0946-672X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>I38ZP9992A</RegistryNumber><NameOfSubstance UI="D008274">Magnesium</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008274" MajorTopicYN="N">Magnesium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Metal exposure</Keyword><Keyword MajorTopicYN="N">Neurodegeneration</Keyword><Keyword MajorTopicYN="N">Neuroprotection</Keyword><Keyword MajorTopicYN="N">Neurotoxicity</Keyword><Keyword MajorTopicYN="N">Ratio</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>2</Day><Hour>18</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37004478</ArticleId><ArticleId IdType="doi">10.1016/j.jtemb.2023.127163</ArticleId><ArticleId IdType="pii">S0946-672X(23)00039-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>